drugset / Trial / NCT03866369
Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
RandomizedSequentialQuadruple-blindTreatment
Summary
The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose study with lanifibranor. The study will consist of up to 3 cohorts of 12 subjects each; therefore, approximately 36 subjects will be included in this study.
Timeline
- Start
- 2019-01-17
- Primary completion
- 2019-08-27
- Completion
- 2019-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanifibranor | Small molecule | — | Oral |
| Background | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.